Mesotheliomas Pleural: Clinical Trials

9 trials for Mesotheliomas Pleural, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 2 recruiting, 2 terminated, 1 completed. 9 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Active not recruiting 3, Recruiting 2, Terminated 2, Completed 1, Unknown 1
Phase 15Terminated 2, Active not recruiting 1, Completed 1, Unknown 1

Follow Mesotheliomas Pleural: new trials by email Literature Review of Mesotheliomas Pleural trials Research Report on Mesotheliomas Pleural

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Sacituzumab Govitecan in People With Mesothelioma
Sacituzumab govitecan-hziy - Mesothelioma, Mesotheliomas Pleural
Phase 2RecruitingMemorial Sloan Kettering Cancer Center332024-06-212026-05-28
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
AMXT1501, DFMO - Cancer, Solid Tumor
Phase 1 / Phase 2TerminatedAminex Therapeutics, Inc.152022-11-292024-12-24
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural
Phase 1 / Phase 2TerminatedTCR2 Therapeutics142022-06-212026-07-13
The IMmunotherapy Pleural 5-ALA PDT
intrapleural photodynamic therapy with videothoracoscopy, Nivolumab Injection - Mesotheliomas Pleural, Malignant Pleural Mesothelioma
Phase 2RecruitingUniversity Hospital, Lille202022-05-092025-09-25
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
RSO-021 - Malignant Pleural Effusion, Malignant Pleural Mesothelioma
Phase 1 / Phase 2CompletedRS Oncology LLC502022-03-312026-07-24
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
Pembrolizumab, Lenvatinib - Mesotheliomas Pleural
Phase 2Active not recruitingThe Netherlands Cancer Institute582021-03-012024-11-05
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
UV1 vaccine + leukine, ipilimumab, nivolumab - Cancer, Cancer, Lung
Phase 2Active not recruitingÅslaug Helland1182020-05-042024-02-29
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant
Phase 1 / Phase 2Active not recruitingTCR2 Therapeutics572019-04-152025-08-27
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST
Phase 1 / Phase 2UnknownInstitut Bergonié7472018-05-042023-03-03

Narrower conditions

Mesothelioma, Malignant (9)  ·  Mesothelioma (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Ovarian Neoplasms (3)  ·  Cholangiocarcinoma (2)  ·  Colorectal Neoplasms (2)  ·  Neoplasms (2)  ·  Stomach Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Biliary Tract Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Diffuse Intrinsic Pontine Glioma (1)

Broader conditions

Adenoma (9)  ·  Lung Diseases (9)  ·  Neoplasms by Histologic Type (9)  ·  Neoplasms by Site (9)  ·  Neoplasms, Glandular and Epithelial (9)  ·  Neoplasms, Mesothelial (9)  ·  Pleural Neoplasms (9)  ·  Respiratory Tract Diseases (9)  ·  Respiratory Tract Neoplasms (9)  ·  Thoracic Neoplasms (9)  ·  Lung Neoplasms (8)  ·  Neoplasms (7)  ·  Adenocarcinoma (4)  ·  Bronchial Neoplasms (4)  ·  Carcinoma (4)

Interventions

Nivolumab (3)  ·  Cyclophosphamide (2)  ·  Ipilimumab (2)  ·  fludarabine (2)  ·  Clinical Trials, Phase II as Topic (1)  ·  Thiostrepton (1)  ·  Thoracic Surgery, Video-Assisted (1)  ·  UV1 vaccine (1)  ·  lenvatinib (1)  ·  pembrolizumab (1)  ·  regorafenib (1)  ·  sargramostim (1)

Sponsors

TCR2 Therapeutics (2)  ·  Aminex Therapeutics, Inc. (1)  ·  Institut Bergonié (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  RS Oncology LLC (1)  ·  The Netherlands Cancer Institute (1)  ·  University Hospital, Lille (1)  ·  Åslaug Helland (1)

Countries

United States (4)  ·  Australia (2)  ·  France (2)  ·  Canada (1)  ·  Denmark (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Arnaud Scherpereel, MD,PhD (1)  ·  James Spicer, MD (1)  ·  Michael Armstrong, MD (1)  ·  Michael Offin, MD (1)  ·  S Burgers, PhD (1)  ·  Sue Lee, MD (1)

Results publications

PMID 34059094, PMID 34965951, PMID 34998048, PMID 37501016, PMID 37844598, PMID 39133306, PMID 40204996, PMID 40579407, PMID 41308680, PMID 42322509, PMID 42448681

NIH funding

2016 (1), 2019 (1)